相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Drug-Drug Interactions and Pharmacogenomic Evaluation in Colorectal Cancer Patients: The New Drug-PIN(R) System Comprehensive Approach
Michela Roberto et al.
PHARMACEUTICALS (2021)
Clinical Implications of Body Mass Index in Metastatic Breast Cancer Patients Treated With Abemaciclib and Endocrine Therapy
Maria Alice Franzoi et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)
Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naive Metastatic Breast Cancer
Richard S. Finn et al.
CLINICAL CANCER RESEARCH (2020)
Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition
Monica Alvarez-Fernandez et al.
CANCER CELL (2020)
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial
Sara M. Tolaney et al.
LANCET ONCOLOGY (2020)
Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer
Pingping Mao et al.
CLINICAL CANCER RESEARCH (2020)
CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions
Rossana Roncato et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer
Neil Portman et al.
BREAST CANCER RESEARCH (2020)
Initial real world treatment patterns and outcomes of Abemaciclib for the treatment of HR+,HER2-metastatic breast cancer
Gebra Cuyun Carter et al.
CANCER RESEARCH (2020)
Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer
Nicholas C. Turner et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Retrospective Analysis of Treatment Patterns and Effectiveness of Palbociclib and Subsequent Regimens in Metastatic Breast Cancer
Jing Xi et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER plus breast cancer
Luigi Formisano et al.
NATURE COMMUNICATIONS (2019)
Everolimus and exemestane for the treatment of metastatic hormone receptor-positive breast cancer patients previously treated with CDK4/6 inhibitor based therapies.
Madeline Cook et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Alpelisib (ALP) plus endocrine therapy (ET) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR plus ), human epidermal growth factor-2-negative (HER2-) advanced breast cancer (ABC): First interim BYLieve study results.
Hope S. Rugo et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A multicenter analysis of abemaciclib after progression on palbociclib in patients (pts) with hormone receptor-positive (HR+)/HER2-metastatic breast cancer (MBC).
Seth Andrew Wander et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Genomic markers of early progression on fulvestrant with or without palbociclib for ER plus advanced breast cancer in the PALOMA-3 trial.
Ben O'Leary et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
Fabrice Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT)
Amelia McCartney et al.
EUROPEAN JOURNAL OF CANCER (2019)
Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2-advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results.
Sara A. Hurvitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
S. -A. Im et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice
Amelia McCartney et al.
FRONTIERS IN ONCOLOGY (2019)
MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21
Anna E. Vilgelm et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis
Mario Giuliano et al.
LANCET ONCOLOGY (2019)
Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials
Valentina Rossi et al.
CANCERS (2019)
Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors
Stefano Fogli et al.
CANCER TREATMENT REVIEWS (2019)
Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time?
Giuseppe Buono et al.
CANCER TREATMENT REVIEWS (2019)
Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review
Kamal Pandey et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
G. N. Hortobagyi et al.
ANNALS OF ONCOLOGY (2018)
4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
F. Cardoso et al.
ANNALS OF ONCOLOGY (2018)
ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors
Angel L. Guerrero-Zotano et al.
CLINICAL CANCER RESEARCH (2018)
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3
Dennis J. Slamon et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
Debu Tripathy et al.
LANCET ONCOLOGY (2018)
Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy
Martina Bonechi et al.
Oncotarget (2018)
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
Pedram Razavi et al.
CANCER CELL (2018)
The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial
Ben O'Leary et al.
CANCER DISCOVERY (2018)
Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway
Zhiqiang Li et al.
CANCER CELL (2018)
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
N. C. Turner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2-Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
George W. Sledge et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Matthew P. Goetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers
Smruthi Vijayaraghavan et al.
NATURE COMMUNICATIONS (2017)
Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer
Luigi Formisano et al.
CLINICAL CANCER RESEARCH (2017)
Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer
Maria Teresa Herrera-Abreu et al.
CANCER RESEARCH (2016)
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
Massimo Cristofanilli et al.
LANCET ONCOLOGY (2016)
Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance
Ping Chen et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Treating cancer with selective CDK4/6 inhibitors
Ben O'Leary et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer
Xiaoyong Fu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Richard S. Finn et al.
LANCET ONCOLOGY (2015)
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer
Nicholas C. Turner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer
Ana Bosch et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS
Barbie Taylor-Harding et al.
ONCOTARGET (2015)
Mechanisms of endocrine resistance in breast cancer: an overview of the proposed roles of noncoding RNA
Erin L. Hayes et al.
BREAST CANCER RESEARCH (2015)
Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
Lawrence M. Gelbert et al.
INVESTIGATIONAL NEW DRUGS (2014)
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Weiyi Toy et al.
NATURE GENETICS (2013)
ERα-Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer
Todd W. Miller et al.
CANCER DISCOVERY (2011)
Lapatinib Restores Hormone Sensitivity with Differential Effects on Estrogen Receptor Signaling in Cell Models of Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer with Acquired Endocrine Resistance
Alexandra F. Leary et al.
CLINICAL CANCER RESEARCH (2010)
Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer
Todd W. Miller et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Mitochondrial DNA content in paired normal and cancerous breast tissue samples from patients with breast cancer
Alex Xiu-Cheng Fan et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2009)
Biological determinants of endocrine resistance in breast cancer
Elizabeth A. Musgrove et al.
NATURE REVIEWS CANCER (2009)
Epigenetic information and estrogen receptor alpha expression in breast cancer
Laura Giacinti et al.
ONCOLOGIST (2006)
分享论文
